[Clinical evaluation of Zaditen syrup in the treatment of children with bronchial asthma].
60 children with atopic asthma were included to the doubleblind study, in order to compare Zaditen and Clemastine. The trial was completed after 12 weeks of treatment. The efficacy was evaluated on the basis of clinical observation, lung function measurements and laboratory data. The Zaditen was shown to have more beneficial clinical effect on studied group than Clemastine. The lung function measurements before and after treatment did not showed much difference, although a significant decrease of the nonspecific bronchial reactivity to histamine was observed in the group receiving Zaditen . This was observed shortly after beginning of the treatment up to 6 weeks. Zaditen sirup was well tolerated and the only side effect observed was a significant weight increase, which could be explained by the elevation of serum sodium ions concentration.
D000293:Adolescent; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents; D002648:Child; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007665:Ketotifen / Q000008:administration & dosage*; D008297:Male
D001993:Bronchodilator Agents; D007665:Ketotifen
Kliniczna ocena skuteczności preparatu Zaditen (syrop) u dzieci z dychawica oskrzelowa.